ATE447965T1 - Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren - Google Patents

Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren

Info

Publication number
ATE447965T1
ATE447965T1 AT01973008T AT01973008T ATE447965T1 AT E447965 T1 ATE447965 T1 AT E447965T1 AT 01973008 T AT01973008 T AT 01973008T AT 01973008 T AT01973008 T AT 01973008T AT E447965 T1 ATE447965 T1 AT E447965T1
Authority
AT
Austria
Prior art keywords
extracellular domain
compositions
cancer treatment
muc1
methods derived
Prior art date
Application number
AT01973008T
Other languages
English (en)
Inventor
Donald W Kufe
Tsuneya Ohno
Original Assignee
Dana Farber Cancer Inst Inc
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Genzyme Corp filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE447965T1 publication Critical patent/ATE447965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01973008T 2000-09-11 2001-09-11 Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren ATE447965T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23184100P 2000-09-11 2000-09-11
PCT/US2001/028548 WO2002022685A2 (en) 2000-09-11 2001-09-11 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom

Publications (1)

Publication Number Publication Date
ATE447965T1 true ATE447965T1 (de) 2009-11-15

Family

ID=22870825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973008T ATE447965T1 (de) 2000-09-11 2001-09-11 Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren

Country Status (10)

Country Link
US (3) US20050053606A1 (de)
EP (1) EP1317278B1 (de)
JP (1) JP5165175B2 (de)
KR (1) KR20030068536A (de)
CN (1) CN1455680A (de)
AT (1) ATE447965T1 (de)
AU (1) AU9263101A (de)
CA (1) CA2421751C (de)
DE (1) DE60140461D1 (de)
WO (1) WO2002022685A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001274947B2 (en) * 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP5165175B2 (ja) * 2000-09-11 2013-03-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
EP2241887B1 (de) * 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostika, Drogenscreening und Behandlung für Krebs
EP1531842A4 (de) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation des zellwachstums durch muc1
JP2005508839A (ja) 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
US9599619B2 (en) * 2002-06-14 2017-03-21 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US8821868B2 (en) * 2002-06-14 2014-09-02 Immunomedics, Inc. Anti-pancreatic cancer antibodies
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
AU2003904201A0 (en) 2003-08-11 2003-08-21 Allen, Barry John Mr Alpha-conjugate of C595 for therapy of pancreatic, prostate and other cancers
DK2363410T3 (en) * 2003-08-26 2018-01-15 Minerva Biotechnologies Corp ISOFORMER OF MUC1
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
EP1697399B1 (de) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1
JP2007523214A (ja) * 2004-02-23 2007-08-16 ジェンザイム コーポレイション デスレセプターリガンド誘導アポトーシスのｍｕｃ１アンタゴニスト増強方法
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
JP2008537095A (ja) * 2005-02-15 2008-09-11 ダナ−ファーバー キャンサー インスティテュート インク． Ｍｕｃ１活性の調節
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
WO2007024940A2 (en) * 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
EP1933624A4 (de) * 2005-10-11 2009-09-16 Univ Washington Zusammensetzungen und verfahren für die behandlung von hypersekretion der atemwege
WO2008111996A2 (en) * 2006-07-20 2008-09-18 Dana-Farber Cancer Institute, Inc. Muc1-ikb kinase complexes and their activities
US20080107661A1 (en) * 2006-07-28 2008-05-08 Dana-Farber Cancer Institute, Inc. MUC1 and ABL
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US8420591B2 (en) * 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008101121A2 (en) * 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
AU2011207189B2 (en) 2008-08-08 2014-01-16 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
EP3130607B1 (de) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1*-antikörper
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
AU2010253834B2 (en) 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
WO2012051518A2 (en) * 2010-10-14 2012-04-19 Amicus Therapeutics, Inc. Compounds and methods for treating or preventing disease conditions associated with alpha-1-antitrypsin
EP2675485A4 (de) * 2011-02-15 2014-10-15 Immunomedics Inc Anti-mucin-antikörper zur frühen erkennung und behandlung von pankreaskrebs
EP2678005A4 (de) * 2011-02-24 2015-06-10 Oncothyreon Inc Glycolipopeptid-impfstoff auf muc1-basis mit einem adjuvans
WO2013026015A1 (en) * 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
JP5413544B1 (ja) 2012-04-27 2014-02-12 コニカミノルタ株式会社 酵素処理工程を含むレクチンを用いた抗原検出方法
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
WO2014199780A1 (ja) * 2013-06-12 2014-12-18 マルハニチロ株式会社 ジペプチジルペプチダーゼｉｖ（ｄｐｐｉｖ）阻害ペプチド化合物、それを含有する組成物、及びその製造方法
US10371704B2 (en) 2013-12-27 2019-08-06 Konica Minolta, Inc. Method for discriminating between prostate cancer and a benign prostate disease
EP3088895A4 (de) * 2013-12-27 2017-08-09 Konica Minolta, Inc. Verfahren zur auswertung von informationen zur diagnose und kit dafür
WO2015116753A1 (en) * 2014-01-29 2015-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (de) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. Einzeldomänen-serumalbuminbindendes protein
WO2018174544A2 (ko) * 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
KR102127421B1 (ko) 2017-03-21 2020-06-26 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3759145A4 (de) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation Diagnoseverfahren unter verwendung von anti-muc1*-antikörpern
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN116536270A (zh) * 2023-01-31 2023-08-04 浙江中医药大学 人卵巢癌细胞系SKOV3-sh-MUC1及其构建方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US5080898A (en) * 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5053489A (en) * 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) * 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
JP3698370B2 (ja) * 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
CA2153068C (en) * 1992-12-31 2007-05-01 Donald Kufe Enhancer sequence for modulating expression in epithelial cells
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
DE69532127T2 (de) * 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge Interaktions-fullensysteme zum nachweis von protein-interaktionen
EP0694808B1 (de) * 1994-07-29 2001-12-05 Dainippon Ink And Chemicals, Inc. Verfahren zur Herstellung von Negativbildern mit ultrahohem Kontrast und photographisches Silberhalogenidmaterial und Entwickler dafür
JPH08176138A (ja) * 1994-12-19 1996-07-09 Mercian Corp イソクマリン誘導体
US6074841A (en) * 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
WO2000000828A1 (en) * 1998-06-26 2000-01-06 Biomira Inc. Method of detecting t-cell activation
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
WO2000034468A2 (en) * 1998-12-11 2000-06-15 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
IL144559A0 (en) * 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
AU2935900A (en) * 1999-03-26 2000-10-16 Firmenich S.A. Cyclic compounds and their use as precursors of fragrant alcohols
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6589981B2 (en) * 2000-02-29 2003-07-08 Ilex Oncology, Inc. Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
JP5165175B2 (ja) * 2000-09-11 2013-03-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
EP1531842A4 (de) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation des zellwachstums durch muc1
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US6716627B2 (en) * 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction

Also Published As

Publication number Publication date
WO2002022685A2 (en) 2002-03-21
EP1317278A2 (de) 2003-06-11
US20050042209A1 (en) 2005-02-24
JP5165175B2 (ja) 2013-03-21
EP1317278B1 (de) 2009-11-11
JP2004515472A (ja) 2004-05-27
US20090232812A1 (en) 2009-09-17
US20050053606A1 (en) 2005-03-10
CA2421751C (en) 2014-02-11
KR20030068536A (ko) 2003-08-21
AU9263101A (en) 2002-03-26
DE60140461D1 (de) 2009-12-24
CN1455680A (zh) 2003-11-12
WO2002022685A3 (en) 2002-09-26
CA2421751A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE447965T1 (de) Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
DE60035204D1 (de) Tyrosinderivate
DE602006012672D1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
NO20070324L (no) Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere
DK1706428T3 (da) Anti-cancer-antistoffer med reduceret komplementfiksering
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
ATE321452T1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
DE60011755D1 (de) Calciumkanalblocker als antikrebsmittel
CY1117722T1 (el) Βελτιωμενη αγωγη του πολλαπλου μυελωματος
MX2010003368A (es) Derivados de imidazol.
ATE431426T1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
MX2022002607A (es) Metodos de tratamiento.
MXPA05005484A (es) Metodo para mejorar las propiedaes fisico-quimicas de composiciones bituminosas y novedosas composiciones bituminosas con propiedades mejoradas y sus usos.
ATE235466T1 (de) Heterozyklen zur behandlung von gutartiger prostata-hyperplasie und deren zwischenprodukte
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
ATE339208T1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
DE60143023D1 (de) Tumorhemmende nitroacridin-zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties